Subchronic glycemic effects after vehicle, metformin, SGLT2I, or combination treatment. Subchronic glycemic effects after vehicle, metformin, SGLT2I, or.

Slides:

Advertisements

Similar presentations

Metabolic effects of TUG‐891 are reduced or absent in GPR120‐deficient mice Metabolic effects of TUG‐891 are reduced or absent in GPR120‐deficient mice.

Advertisements

AG-221 induces the differentiation of IDH2R140Q blasts along myeloid lineages in primary human AML xenograft models. AG-221 induces the differentiation.

Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.

Metabolic effects of K107R and rosiglitazone treatment.

Fig. 1. Glycemic variability in three hypothetical patients who have the same mean blood glucose concentration. Patient B has relatively small variations.

Treatment of SFTSV-infected IFNAR−/− mice with T-705 or ribavirin.

TFE3 prevents diet‐induced obesity and metabolic syndrome

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Effects of 5 yr of GH substitution in 118 GH-deficient adults on serum concentrations of TC, HDL-C, LDL-C and TG as well as on blood glucose, serum insulin.

Diet-Induced Obese Mice Retain Endogenous Leptin Action

Improvement of insulin sensitivity by treatment of the annexin A1 receptor agonist in HFD mice. Improvement of insulin sensitivity by treatment of the.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Urine ammonia is highly correlated with plasma K

Therapeutic role of TR in HFD‐established diabetic mice

Fig. 5 Treatment with an OX40 agonist antibody of 3-week-old HBVtgRag−/− mice or mice with chronic HBV disease results in an altered immune response to.

Supplementary Figure 5: Effect of S48168 on normalized organ and skeletal muscle weights after 12 weeks of treatment for all the experimental groups from.

Unchanged worm burden and microfilaremia in basophil-deficient mice compared with their basophil-competent littermates. Unchanged worm burden and microfilaremia.

Cyp8b1−/− mice have improved islet insulin secretion and increased islet insulin content but unchanged β-cell mass. Cyp8b1−/− mice have improved islet.

Influence on chronic morphine on pain.

Glucose, insulin, and AGE levels during an OGC before and after RT

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

1018-NT-β-cell clusters protect mice from STZ-induced diabetes.

WASH cKO mice display a normal pancreatic development.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

GSIS. GSIS. In vivo: serum insulin levels at fasting state and 30 min after glucose injection (A) and the fold change in serum insulin after glucose loading.

Liver AMPK is activated by oral administration of canagliflozin in mice, but this does not explain changes in RER. A: Phosphorylation of AMPK, ACC, and.

A: The change of plasma glucose in opioid μ-receptor knockout diabetic mice and wild-type controls receiving an oral intake of metformin (100 mg/kg). A:

PMPs survive STZ cytotoxicity and produce larger colonies with a higher yield of insulin+ progeny. PMPs survive STZ cytotoxicity and produce larger colonies.

A: Insulin-stimulated total, oxidative, and nonoxidative glucose disposal in subjects with NGT (open bars), IFG (dotted bars), IGT (striped bar), IFG/IGT.

Modulation of insulin sensitivity by IL-6 in mice: A lack of PTP1B prevents chronic effects of IL-6. Modulation of insulin sensitivity by IL-6 in mice:

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

Measurement of insulin release from islets evoked by glucose, diazoxide, and high K+. Measurement of insulin release from islets evoked by glucose, diazoxide,

Glucose tolerance in WT and TRPM2-KO mice.

Metformin and rapamycin decreased tumor weights in obese prediabetic mice. Metformin and rapamycin decreased tumor weights in obese prediabetic mice. A:

Insulin sensitivity in athletes and sedentary normal-weight and obese, young, and old individuals. Insulin sensitivity in athletes and sedentary normal-weight.

HFHC/STZ guinea pigs develop insulin-independent diabetes that is responsive to oral antihyperglycemic therapy. HFHC/STZ guinea pigs develop insulin-independent.

The effect of VSG on body weight and body fat in GLP-1r KO mice.

GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. Beginning.

A: Chemical structure of pterosin A

Treatment of ob/ob mice with TTR-ASOs reduces adipose tissue inflammation. Treatment of ob/ob mice with TTR-ASOs reduces adipose tissue inflammation. A:

Chop deletion preserves β-cell function in P58IPK−/− mice.

Adoptive transfer of purified activated G9Cα−/−

Effect of PEDF+DHA treatment on wound healing in diabetic corneas.

GLP-1 and gastrin combination therapy induces immunoregulatory cell activity in NOD mice. GLP-1 and gastrin combination therapy induces immunoregulatory.

Atrasentan reduces albuminuria in diabetic apoE KO mice.

High-glucose–induced insulin resistance in TRIB3 MOE mice.

Hepatic fuel metabolism in male 5αR1-KO and WT mice

Mice fed GP-SPI diet show improved fasting glucose and oral glucose tolerance. Mice fed GP-SPI diet show improved fasting glucose and oral glucose tolerance.

Insulin resistance and hepatic steatosis in ASKO mice.

Treatment of high-fat diet–fed mice with TTR-ASOs decreases circulating TTR and RBP4 levels, and improves insulin sensitivity. Treatment of high-fat diet–fed.

Treatment of ob/ob mice with TTR-ASOs improves insulin sensitivity.

Systemic treatment with AMPK activators decreases TRPA1 associated with membrane in DRG neurons of db/db mice. Systemic treatment with AMPK activators.

Effects of Rosi treatment on ASKO mice.

Effects of berberine on in vivo metabolism in two animal models of insulin resistance. Effects of berberine on in vivo metabolism in two animal models.

Energy stores in quadriceps muscles at rest (white bars) and after treadmill exercise (black bars) in WT and HSL KO mice. Energy stores in quadriceps muscles.

GTTs and ITTs. A: GTTs of WT (◇), LepTg (♦), Akita (open circles), and LepTg:Akita (closed circles) mice at 8 and 16 weeks of age. GTTs and ITTs. A: GTTs.

Oral glucose tolerance testing during hospitalization and at 4 months after infarction. Oral glucose tolerance testing during hospitalization and at 4 months.

Loss of Phb2 in β-cells induces development of diabetes over a 3-week period in β-Phb2−/− mice. Loss of Phb2 in β-cells induces development of diabetes.

Effect of cocaine (COC) withdrawal on learning.

Blood glucose levels in chicken embryos.

(A) Oral glucose tolerance test (OGTT) glucose and (C) natural logarithm of insulin responses over time with SEM bars comparing the first tertile to the.

Effects of rhein on FBG (A) and glucose intolerance (B) in db/db mice.

Study protocol. Study protocol. Eight subjects (seven men and one woman) with type 2 diabetes entered the study. The subjects discontinued their antidiabetic.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

mTORC1 is required for malignant transformation in the Eμ-Myc model.

Fig. 1. The HCN channel blocker ivabradine (IVA) is analgesic in a mouse model of type 1 diabetes. The HCN channel blocker ivabradine (IVA) is analgesic.

Curative effect of W+T treatment in vivo.

A: Glucose levels during basal-bolus and SSI treatment.

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Fig. 3. Effects of SFN in mice with diet-induced diabetes.

Presentation transcript:

Subchronic glycemic effects after vehicle, metformin, SGLT2I, or combination treatment. Subchronic glycemic effects after vehicle, metformin, SGLT2I, or combination treatment. After an initial blood glucose and HbA1c measurement, 8-week-old (A) db/db and normoglycemic wt males (n = 10/group) or 9-week-old (B) diabetic Tallyho/JngJ males (n = 10/group) were treated orally once per day prior to the dark-phase onset. After 14 intervention days and 18 ± 2 h posttreatment, blood glucose concentrations and HbA1c were determined again. For db/db mice (n = 4–7/group) (A [right panel]) and Tallyho/JngJ mice (n = 7/group) (B [right panel]), the relative HbA1c change between prior and posttreatment is shown. C: In chronically diabetic, 22-week-old Tallyho/JngJ males, blood glucose concentrations were measured after three and seven treatments 12 ± 2 h posttreatment (n = 6/group). Data represent means ± SEM (ANOVA, Bonferroni). d, day. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Open bars/circles, vehicle; black bars, metformin; striped bars, SGLT2I; yellow bars/squares, combination metformin and SGLT2I. Susanne Neschen et al. Diabetes 2015;64:284-290 ©2015 by American Diabetes Association